# Exelixis, Inc.  Share Price Target ‘$36.89’, now -.6% Downside Potential

- Link: https://www.directorstalkinterviews.com/exelixis-inc-share-price-target-36-89-now-6-downside-potential/4121187520
- Published: 2025-02-25T15:11:56+00:00
- Author: Charlotte Edwards

**Exelixis, Inc.** with ticker code (EXEL) have now 23 market analysts covering 
the stock. The analyst consensus now points to a rating of ‘buy’. The range between
the high target price and low target price is between $45.00 and $23.00 suggesting
an average analyst share price target price of $36.89. (at the time of writing).
Given that the stocks previous close was at $37.13 this would imply there is a potential
downside of -.6%. The 50 day moving average now sits at $34.30 and the 200 moving
average now moves to $28.33. The market cap for the company is 10.24B. The price
for the stock stands currently at: $36.59 USD

 The potential market cap would be $10,173,332,917 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 20.79, revenue per share of $7.48
and a 14.64% return on assets.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines
and combination regimens at the forefront of cancer care. It has four products, 
including its flagship molecule, cabozantinib, which is an inhibitor of multiple
tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved
as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and
in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for
hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic
medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor
of MEK approved as part of multiple combination regimens to treat specific forms
of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR) approved the treatment of hypertension.

Share on:
